Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion.
Kim
Kwan Soo
KS
Chang
Hae Ran
HR
Song
Sujeong
S
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005584:Fovea Centralis / Q000098:blood supply*; D006801:Humans; D007267:Injections; D007511:Ischemia / Q000139:chemically induced*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D012170:Retinal Vein Occlusion / Q000139:chemically induced*; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab